Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: A multivariate analysis of expression of p53, retinoblastoma, and related proteins
- 1 September 2003
- journal article
- research article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 13 (5), 598-606
- https://doi.org/10.1046/j.1525-1438.2003.13391.x
Abstract
Accurate estimation of prognosis of ovarian cancer is difficult. For this report, in a group of 73 patients with ovarian adenocarcinomas, clinical factors and protein expression status of p53, retinoblastoma (Rb), and related proteins were evaluated for potential prognostic values. Clinical factors included FIGO stage, age, histopathologic type, and protein expression of p53, Rb, MDM2, p14ARF, p21WAF( 1 )/CIP( 1 ) was determined by an immunohistochemical technique. Univariate Cox proportional hazard regression analysis was used to determine the significant prognostic value of FIGO stage (P < 0.0001), p53 status (0.0021), and patient age (P = 0.0255), and we report here, for the first time, the significant (P = 0.0072) prognostic value of Rb status. Histopathologic type and MDM2, p14ARF, p21WAF( 1 )/CIP( 1 ) status did not show any prognostic value. To examine further the independence of prognostic values, we next applied multivariate analysis: We found that FIGO stage (P < 0.0001) and p53 status (P = 0.0108) were independent prognostic factors, while age and Rb status were not. Independence of prognostic value of p53 has heretofore been controversial, but we found a definite independent prognostic value for p53 status in ovarian adenocarcinomas. We also found that selection of appropriate antibodies for immunohistochemistry was essential to obtain significant results. We used five kinds of antibodies for p53 immunolocalization, and correlation with prognosis was obtained by three of these with different grades of statistical significance.Keywords
This publication has 29 references indexed in Scilit:
- Assessing TP53 status in human tumours to evaluate clinical outcomeNature Reviews Cancer, 2001
- p53 Mutation Is Infrequent in Clear Cell Carcinoma of the OvaryGynecologic Oncology, 2001
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- MDM2 — master regulator of the p53 tumor suppressor proteinGene, 2000
- Prognostic Significance of p53 and p21waf1/cip1 Immunoreactivity in Epithelial Cancers of the OvaryGynecologic Oncology, 1999
- Molecular analysis of the retinoblastoma gene in primary ovarian cancer cellsInternational Journal of Cancer, 1994
- Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancerInternational Journal of Cancer, 1992
- Mutations in the p53 gene occur in diverse human tumour typesNature, 1989
- Mesonephroid carcinoma of the ovary: A study of 95 cases from the Emil Novak Ovarian Tumor RegistryGynecologic Oncology, 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958